{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:11:38Z","timestamp":1767625898662,"version":"3.33.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.msard.2023.104840","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T01:09:09Z","timestamp":1687309749000},"page":"104840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs"],"prefix":"10.1016","volume":"77","author":[{"given":"Berenice A.","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jefferson","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 I","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio E","family":"Correa-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Galleguillos Goiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando","family":"Garcea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Hamuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Navas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan I","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio F.","family":"Farez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104840_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.msard.2019.07.026","article-title":"Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab","volume":"35","author":"Aguirre","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"issue":"13","key":"10.1016\/j.msard.2023.104840_bib0006","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1177\/13524585211039750","article-title":"Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary","volume":"27","author":"Alonso","year":"2021","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2023.104840_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102886","article-title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM","volume":"51","author":"Alonso","year":"2021","journal-title":"Multiple sclerosis and related disorders"},{"issue":"5","key":"10.1016\/j.msard.2023.104840_bib0008","article-title":"SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry","volume":"8","author":"Arrambide","year":"2021","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.msard.2023.104840_bib0010","first-page":"752","volume":"35","author":"Bartalesi","year":"2017","journal-title":"Clinical and experimental rheumatology"},{"issue":"15","key":"10.1016\/j.msard.2023.104840_bib0011","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.msard.2023.104840_bib0012","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2023.104840_bib0013","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1177\/0091270011427908","article-title":"Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study","volume":"52","author":"Boulton","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/14740338.2018.1483330","article-title":"Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis","volume":"17","author":"Buonomo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0015","article-title":"Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations","volume":"9","author":"Cabreira","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"The Lancet. Neurology"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0017","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"The Lancet. Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.riam.2019.09.001","article-title":"Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies","volume":"37","author":"Candel","year":"2020","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.msard.2023.104840_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.msard.2019.05.024","article-title":"Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients","volume":"33","author":"Carnero Contentti","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.msard.2023.104840_bib0019","article-title":"Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients","author":"Carnero Contentti","year":"2020","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2023.104840_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102420","article-title":"Infections in patients with multiple sclerosis: A national cohort study in Sweden","volume":"45","author":"Castelo-Branco","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.idc.2009.10.010","article-title":"Pneumocystis jirovecii Pneumonia","volume":"24","author":"Catherinot","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.msard.2023.104840_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow fever control: current epidemiology and vaccination strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Tropical diseases, travel medicine and vaccines"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"Journal of neurology"},{"key":"10.1016\/j.msard.2023.104840_bib0036","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinimag.2018.11.005","article-title":"Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings","volume":"54","author":"Chong","year":"2019","journal-title":"Clin Imaging"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0023","doi-asserted-by":"crossref","first-page":"ofy356","DOI":"10.1093\/ofid\/ofy356","article-title":"Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis","volume":"6","author":"Ciardi","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0024","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/1352458516688350","article-title":"Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab","volume":"23","author":"Clerico","year":"2017","journal-title":"Multiple sclerosis"},{"issue":"5","key":"10.1016\/j.msard.2023.104840_bib0025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"9856","key":"10.1016\/j.msard.2023.104840_bib0026","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2023.104840_bib0028","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104840_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420982134","article-title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","volume":"14","author":"Coles","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial","volume":"11","author":"Comi","year":"2012","journal-title":"The Lancet. Neurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.msard.2023.104840_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Multiple sclerosis and related disorders"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0032","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nature reviews. Neurology"},{"key":"10.1016\/j.msard.2023.104840_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118072","article-title":"Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation","volume":"429","author":"Cristiano","year":"2021","journal-title":"Journal of the neurological sciences"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0037","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz015","article-title":"Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?","volume":"26","author":"de Jong","year":"2019","journal-title":"Journal of travel medicine"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0038","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0039","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40263-014-0160-8","article-title":"Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis","volume":"28","author":"Du Pasquier","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/fcp.12394","article-title":"Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab","volume":"33","author":"Durrieu","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0041","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.nrl.2018.03.015","article-title":"Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab","volume":"35","author":"Eichau","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"issue":"8","key":"10.1016\/j.msard.2023.104840_bib0042","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0043","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0044","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.msard.2023.104840_bib0045","article-title":"Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register","author":"Evangelou","year":"2020","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2023.104840_bib0046","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneurol.2011.131","article-title":"Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis","volume":"68","author":"Farez","year":"2011","journal-title":"Archives of neurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0047","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1191\/135248506ms1318oa","article-title":"A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients","volume":"12","author":"Ford","year":"2006","journal-title":"Multiple sclerosis"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0048","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cns.12067","article-title":"Report of three cases of herpes zoster during treatment with natalizumab","volume":"19","author":"Fragoso","year":"2013","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.msard.2023.104840_bib0049","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2016.01.005","article-title":"Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab","volume":"6","author":"Fragoso","year":"2016","journal-title":"Multiple sclerosis and related disorders"},{"issue":"8","key":"10.1016\/j.msard.2023.104840_bib0050","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/1352458519832259","article-title":"Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy","volume":"25","author":"Gerevini","year":"2019","journal-title":"Multiple sclerosis"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0051","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10654-019-00595-2","article-title":"Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway","volume":"35","author":"Ghaderi","year":"2020","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"10.1016\/j.msard.2023.104840_bib0052","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"12","key":"10.1016\/j.msard.2023.104840_bib0054","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2023.104840_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"12","key":"10.1016\/j.msard.2023.104840_bib0056","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Multiple sclerosis"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0057","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2023.104840_bib0058","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.msard.2023.104840_bib0059","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","article-title":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature","volume":"9","author":"Grebenciucova","year":"2016","journal-title":"Multiple sclerosis and related disorders"},{"issue":"13","key":"10.1016\/j.msard.2023.104840_bib0060","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1177\/13524585211030214","article-title":"Dengue fever in a multiple sclerosis patient taking Ocrelizumab","volume":"27","author":"Guerra","year":"2021","journal-title":"Multiple sclerosis"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0061","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0b013e3181cef810","article-title":"Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis","volume":"74","author":"Gutwinski","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0062","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"11","key":"10.1016\/j.msard.2023.104840_bib0063","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0064","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","article-title":"Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies","volume":"17","author":"Holmoy","year":"2017","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0065","article-title":"Risk of MS relapse after yellow fever vaccination: A self-controlled case series","volume":"7","author":"Huttner","year":"2020","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"17","key":"10.1016\/j.msard.2023.104840_bib0066","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Investigators","year":"2008","journal-title":"The New England journal of medicine"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0067","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Annals of neurology"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0068","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","article-title":"Epidemiology of multiple sclerosis: results from a large observational study in the UK","volume":"262","author":"Jick","year":"2015","journal-title":"Journal of neurology"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0069","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years","volume":"6","author":"Johnson","year":"2000","journal-title":"Multiple sclerosis"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458520949158","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","volume":"28","author":"Jordan","year":"2022","journal-title":"Multiple sclerosis"},{"issue":"9805","key":"10.1016\/j.msard.2023.104840_bib0072","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104840_bib0073","unstructured":"Kathryn Fitch, S.J.B., Mar\u00eda Dolores Aguilar, Bernard Burnand, Juan Ram\u00f3n LaCalle, Pablo L\u00e1zaro, Mirjam van het Loo, Joseph McDonnell, John Paul Vader, James P. Kahan., 2010. Rand Corporation. The RAND\/UCLA appropriateness method user's manual. Santa Monica: RAND; 2001. Development of Good Practice Guidelines. \u2018\u2018Formal Consensus\u2019\u2019 Method. (Accessed 2015."},{"issue":"8","key":"10.1016\/j.msard.2023.104840_bib0075","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1352458520977132","article-title":"Expanding spectrum of opportunistic infections associated with dimethyl fumarate","volume":"27","author":"Kim","year":"2021","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2023.104840_bib0076","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836571","article-title":"Risks and risk management in modern multiple sclerosis immunotherapeutic treatment","volume":"12","author":"Klotz","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0077","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/1352458511428082","article-title":"Herpes encephalitis during natalizumab treatment in multiple sclerosis","volume":"18","author":"Kwiatkowski","year":"2012","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.msard.2023.104840_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101503","article-title":"Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis","volume":"38","author":"Lau","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0079","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2023.104840_bib0081","article-title":"Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders","author":"Louapre","year":"2020","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0082","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.msard.2023.104840_bib0083","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"The Lancet. Neurology"},{"issue":"23","key":"10.1016\/j.msard.2023.104840_bib0084","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1212\/WNL.0000000000000495","article-title":"Intensive care unit admission in multiple sclerosis: increased incidence and increased mortality","volume":"82","author":"Marrie","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0085","first-page":"258","article-title":"Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?","volume":"28","author":"Mazzitelli","year":"2020","journal-title":"Infez Med"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0086","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"10.1016\/j.msard.2023.104840_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103368","article-title":"inverted question mark Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis","volume":"57","author":"Michelena","year":"2022","journal-title":"Multiple sclerosis and related disorders"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0088","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Multiple sclerosis"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0089","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"8","key":"10.1016\/j.msard.2023.104840_bib0090","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","article-title":"Hospital admission due to infections in multiple sclerosis patients","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0091","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1352458517711569","article-title":"Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab","volume":"24","author":"Mulero","year":"2018","journal-title":"Multiple sclerosis"},{"issue":"14","key":"10.1016\/j.msard.2023.104840_bib0092","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"12","key":"10.1016\/j.msard.2023.104840_bib0093","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00296-016-3575-3","article-title":"Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy","volume":"36","author":"Ozguler","year":"2016","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.msard.2023.104840_bib0094","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.neurol.2021.04.011","article-title":"Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society","volume":"177","author":"Papeix","year":"2021","journal-title":"Rev Neurol (Paris)"},{"issue":"14","key":"10.1016\/j.msard.2023.104840_bib0095","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1177\/13524585211006372","article-title":"Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?","volume":"27","author":"Papeix","year":"2021","journal-title":"Multiple sclerosis"},{"issue":"5","key":"10.1016\/j.msard.2023.104840_bib0096","article-title":"COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0097","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","article-title":"Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy","volume":"78","author":"Patel","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2023.104840_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: A multi-database study","volume":"41","author":"Persson","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0099","doi-asserted-by":"crossref","first-page":"e1965","DOI":"10.1371\/journal.pntd.0001965","article-title":"Immunosuppression and Chagas disease: a management challenge","volume":"7","author":"Pinazo","year":"2013","journal-title":"PLoS neglected tropical diseases"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/07853890.2018.1461919","article-title":"Adult hospital admissions associated with multiple sclerosis in Finland in 2004-2014","volume":"50","author":"Pirttisalo","year":"2018","journal-title":"Annals of medicine"},{"key":"10.1016\/j.msard.2023.104840_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102328","article-title":"Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009-2018","volume":"44","author":"Pirttisalo","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0102","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.msard.2023.104840_bib0003","doi-asserted-by":"crossref","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group 1998. Lancet 352 (9139), 1498-1504. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0103","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.3390\/ijms160714669","article-title":"Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis\u2013Report of Two Cases","volume":"16","author":"Rau","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0105","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s10067-021-05581-2","article-title":"Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response","volume":"40","author":"Ringer","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.msard.2023.104840_bib0106","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1352458520952310","article-title":"Vaccinations in patients with multiple sclerosis: A Delphi consensus statement","volume":"27","author":"Riva","year":"2021","journal-title":"Multiple sclerosis"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0107","first-page":"494","article-title":"Cervical dysplasia associated with the use of natalizumab","volume":"71","author":"Rolfes","year":"2013","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0108","first-page":"399","article-title":"Re-emergence of yellow fever in the neotropics - quo vadis?","volume":"4","author":"Sacchetto","year":"2020","journal-title":"Emerging topics in life sciences"},{"issue":"12","key":"10.1016\/j.msard.2023.104840_bib0109","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.msard.2013.02.006","article-title":"Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion","volume":"2","author":"Sharma","year":"2013","journal-title":"Multiple sclerosis and related disorders"},{"issue":"2","key":"10.1016\/j.msard.2023.104840_bib0111","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101509","article-title":"Opportunistic tropical infections in immunosuppressed patients","volume":"34","author":"Shu Kurizky","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.msard.2023.104840_bib0113","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1352458509107010","article-title":"Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients","volume":"15","author":"Smestad","year":"2009","journal-title":"Multiple sclerosis"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0114","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Annals of neurology"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0116","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3346\/jkms.2014.29.1.38","article-title":"Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy","volume":"29","author":"Suh","year":"2014","journal-title":"J Korean Med Sci"},{"issue":"7","key":"10.1016\/j.msard.2023.104840_bib0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0001","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104840_bib0117","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.579438","article-title":"New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab","volume":"11","author":"Toboso","year":"2020","journal-title":"Frontiers in neurology"},{"issue":"11","key":"10.1016\/j.msard.2023.104840_bib0118","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1177\/1352458518807088","article-title":"Warts and all: Fingolimod and unusual HPV-associated lesions","volume":"25","author":"Triplett","year":"2019","journal-title":"Multiple sclerosis"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0119","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/13524585211069068","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021","volume":"28","author":"Tur","year":"2022","journal-title":"Multiple sclerosis"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0120","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.rmed.2015.01.018","article-title":"Respiratory dysfunction in multiple sclerosis","volume":"109","author":"Tzelepis","year":"2015","journal-title":"Respir Med"},{"issue":"20","key":"10.1016\/j.msard.2023.104840_bib0122","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2023.104840_bib0121","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Multiple sclerosis"},{"year":"2015","series-title":"Guidelines on the management of latent tuberculosis infection","key":"10.1016\/j.msard.2023.104840_bib0004"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0123","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12883-020-01741-0","article-title":"Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report","volume":"20","author":"Wienemann","year":"2020","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1016\/j.msard.2023.104840_bib0124","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Multiple sclerosis"},{"issue":"10","key":"10.1016\/j.msard.2023.104840_bib0125","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2023.104840_bib0126","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Multiple sclerosis"},{"issue":"4","key":"10.1016\/j.msard.2023.104840_bib0127","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nature reviews. Neurology"},{"key":"10.1016\/j.msard.2023.104840_bib0128","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","author":"Wray","year":"2018","journal-title":"Multiple sclerosis"},{"issue":"1","key":"10.1016\/j.msard.2023.104840_bib0074","article-title":"Global health security threats and related risks in Latin America. Global Security: Health","volume":"6","author":"Yeh","year":"2021","journal-title":"Science and Policy"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:09:34Z","timestamp":1737641374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823003425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":128,"alternative-id":["S2211034823003425"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104840","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104840"}}